Based on the excerpt you provided, the press‑release summary does not include the specific guidance figures that Eton Pharmaceuticals gave for:
- Q3 2025 earnings (net income) and revenue
- Full‑year 2025 earnings (net income) and revenue
The summary only notes that the company “reported financial results for the quarter ended June 30, 2025” and that the release is dated August 7, 2025, but it does not list the actual guidance numbers.
To answer your question accurately, we would need the complete press‑release (or another source) that contains the guidance details. If you can provide the full text of the release or a link to the complete announcement, I can extract the Q3 2025 and full‑year 2025 earnings and revenue guidance for you.
Other Questions About This News
Are there any red flags in the financial statements (e.g., revenue recognition, unusual expenses) that warrant scrutiny?
Are there any upcoming catalysts (clinical trial readouts, FDA decisions) that could affect the stock?
Did the company announce any new collaborations, licensing deals, or acquisitions?
How does the reported EBITDA/EBIT margin compare with peers in the rare‑disease space?
What impact might the reported results have on the stock’s valuation multiples?
What were the key drivers behind any revenue or profit changes in this quarter?
What were the results for the company's lead drug candidates and pipeline milestones?
What is the outlook for the company's R&D spending and its impact on future earnings?
Are there any notable changes in the company's cash flow, cash balance, or debt levels?
Did any regulatory events (e.g., FDA approvals or setbacks) occur during the quarter?
Did the company beat or miss consensus analyst estimates for revenue, EPS, and guidance?
Did the company raise or cut its dividend or share‑repurchase program?
How did Eton's Q2 2025 revenue and earnings compare to the same quarter last year?
What is the outlook for the company's flagship product sales and market share?